Navigation Links
Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
Date:11/27/2012

ALLEGAN, Mich., Nov. 27, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, Cobrek Pharmaceuticals, Inc., received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%, the generic equivalent of Luxiq® Foam. Perrigo has manufactured the product and is preparing to commence commercial shipments on January 15, 2013, consistent with the date certain launch settlement. Cobrek was first to file, making the product eligible for 180 days of marketing exclusivity.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Betamethasone valerate foam 0.12% is indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). Brand annual sales were approximately $40 million.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is our sixth product approval using a foam dosage form, which requires specialized development and manufacturing capabilities. It is an example of the excellent partnership we have with Cobrek and we are committed to making quality healthcare more affordable for our customers and drive value for our shareholders."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company, based in Allegan, Michigan, has grown to become a leading global provider of quality, affordable healthcare products. The Company develops, manufactures and distributes over-the-counter ("OTC") and generic prescription ("Rx") pharmaceuticals, nutritional products and active pharmaceutical ingredients ("API") and is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo's mission is to offer uncompromised "quality, affordable healthcare products", and it does so across a wide variety of product categories pri
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
2. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
3. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
4. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
5. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
6. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
7. Perrigo Company To Present At The William Blair Growth Stock Conference
8. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
9. Perrigo Company Announces Quarterly Dividend
10. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
11. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... 27, 2015  The Academy of Managed Care ... Administration,s (FDA,s) draft guidance and proposed rule that ... to bear a nonproprietary name with an FDA-designated ... a decision from the FDA on the naming ... stakeholders urging the agency to use the same ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
Breaking Medicine Technology:Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... CHARENTON-LE-PONT, France , July 13, 2010 ... its,commitment not to create any dilution for existing shareholders. The two-part,transaction was ... were cancelled to offset the dilutive impact of the, ... granted, to employees., - ...
... NEW YORK , July 12 DrChrono.com , the premier ... world-renowned iPad EMR app , featuring the ability to build macros and customizable ... DrChrono.com and its iPad EMR ... Wall Street Journal , Newsday , The Health ...
Cached Medicine Technology:Essilor Cancels Four Million Shares 2DrChrono.com iPad EMR Introduces Macros, Customizable SOAP Notes 2DrChrono.com iPad EMR Introduces Macros, Customizable SOAP Notes 3DrChrono.com iPad EMR Introduces Macros, Customizable SOAP Notes 4
(Date:8/28/2015)... ... 28, 2015 , ... Approximately 2,000 United Methodists are expected ... helping children, a thank you to the many creative and generous ways in ... United Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium ...
(Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
(Date:8/28/2015)... TX (PRWEB) , ... August 28, 2015 , ... For ... Center is taking part with their subsidiary USPI Tenet Health. , The American Heart ... fight heart disease and stroke. They believe that together, a difference can be made. ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily ... FDA clearance for results that last for two years, the longest of any cellulite ... who are looking for a long-lasting, effective solution for their cellulite, according to Dr. ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... On ... Western Michigan, joined as sponsor of the “Music With A Mission” benefit concert in ... behind the event was to raise money to support music education programs in the ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... the second year in a row, the American Red Cross and ... their families around the world this holiday season. This year a ... 300 military installations and hospitals around the world. , ... , There are many ways you can ...
... 2007, - ... - Debt financing is ... VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ - CRH Medical Corporation (CRM:TSX-V) announced today ... and unveiled a new strategy designed to mitigate the need to obtain ...
... Streamline Health Solutions, Inc. (Nasdaq: STRM ) ... E. Vick, Jr., as the Company,s interim Chief Financial Officer ... Officer. Mr. Vick may be considered as a candidate ... Chief Financial Officer, Mr. Vick will also continue to serve ...
... Watson Pharmaceuticals,Inc. (NYSE: WPI ... announced,that its subsidiary, Watson Laboratories, Inc., has ... Food and Drug Administration on its Abbreviated,New ... (XL) in the 150 mg strength. ...
... may be affected by phthalates in these products, experts ... exposed to a common hairspray chemical while at work ... an abnormally placed urinary opening, a new report says. ... nail and hair products contain chemicals called phthalates, such ...
... WASHINGTON, Nov. 26 Talk about being a Grinch! On ... of the government workforce -- are having their benefits cut ... , That,s right, BCBS has drastically altered a ... upon for their healthcare coverage -- and hasn,t bothered to ...
Cached Medicine News:Health News:Remember to Send 'Holiday Mail For Heroes' and Thank a Service Member this Thanksgiving 2Health News:CRH Medical reports Q3 2008 results 2Health News:CRH Medical reports Q3 2008 results 3Health News:CRH Medical reports Q3 2008 results 4Health News:CRH Medical reports Q3 2008 results 5Health News:CRH Medical reports Q3 2008 results 6Health News:Streamline Health Announces Appointment of Interim Chief Financial Officer 2Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg 2Health News:Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, We're Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged 2
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... management of diabetes in order to maintain tight ... effective way to reduce or even prevent diabetes-related ... improving a diabetes patients quality of life, however, ... have been the guiding factors in the development ...
... by the CGMS System Gold can assist ... program based on detailed glycemic profiles. Its ... improve motivation and collaboration with patients.1, ... with all diabetes patients, it may be ...
... Biographer is intended for detecting trends and ... (aged 18 and older) and children/adolescents (aged ... supervise the use of the G2 Biographer ... intended to supplement, not replace, conventional blood ...
Medicine Products: